New and future immunomodulatory therapy in type 1 diabetes

Trends in Molecular Medicine

Volumn 18, Issue 3, 2012, Pages 173-181

  Tooley, James E ^a   Waldron Lynch, Frank ^a   Herold, Kevan C ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

Biologics; Immunotherapy; Metabolic therapy; Type 1 diabetes

Indexed keywords

ABATACEPT; CD20 ANTIBODY; CD3 ANTIBODY; CYCLOSPORIN; GLUTAMATE DECARBOXYLASE 65; HEAT SHOCK PROTEIN 60; IMMUNOMODULATING AGENT; INSULIN; INTERLEUKIN 2; MILK PROTEIN; OMEGA 3 FATTY ACID; OTELIXIZUMAB; RAPAMYCIN; RITUXIMAB; TEPLIZUMAB; VITAMIN D;

ANTIGEN SPECIFICITY; DIET THERAPY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NONHUMAN; REVIEW; TREATMENT RESPONSE;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; NUTRITION THERAPY;

EID: 84858013882     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.01.001     Document Type: Review

References (79)

1. Nejentsev S., et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 2007, 450:887-892.
2. Erlich H., et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 2008, 57:1084-1092.
3. Redondo M.J., et al. Concordance for islet autoimmunity among monozygotic twins. N. Engl. J. Med. 2008, 359:2849-2850.
4. Harjutsalo V., et al. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008, 371:1777-1782.
5. TEDDY Study Group The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. Pediatr. Diabetes 2007, 8:286-298.
6. Steffes M.W., et al. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003, 26:832-836.
7. Stiller C., et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984, 223:1362-1367.
8. Bougnères P.F., et al. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 1990, 39:1264-1272.
9. Baekkeskov S., et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990, 347:151-156.
10. Tian J., et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat. Med. 1996, 2:1348-1353.
11. Tisch R., et al. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 1998, 47:894-899.
12. Pleau J.M., et al. Prevention of autoimmune diabetes in nonobese diabetic female mice by treatment with recombinant glutamic acid decarboxylase (GAD 65). Clin. Immunol. Immunopathol. 1995, 76:90-95.
13. Agardh C.D., et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J. Diabetes Complications 2005, 19:238-246.
14. Wherrett D.K., et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011, 378:319-327.
15. Ludvigsson J., et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N. Engl. J. Med. 2008, 359:1909-1920.
16. Nakayama M., et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005, 435:220-223.
17. Zhang Z.J., et al. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:10252-10256.
18. Bergerot I., et al. Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes. J. Autoimmun. 1994, 7:655-663.
19. Harrison L.C., et al. Aerosol insulin induces regulatory CD8 γδ T cells that prevent murine insulin-dependent diabetes. J. Exp. Med. 1996, 184:2167-2174.
20. Skyler J.S., et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial - Type 1. Diabetes Care 2005, 28:1068-1076.
21. The Diabetes Prevention Trial - Type 1 Diabetes Study Group Effects of insulin in relatives of patients with type 1 diabetes mellitus. N. Engl. J. Med. 2002, 346:1685-1691.
22. Näntö-Salonen K., et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008, 372:1746-1755.
23. Pozzilli P., et al. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia 2000, 43:1000-1004.
24. Chaillous L., et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group. Lancet 2000, 356:545-549.
25. Fourlanos S., et al. Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes 2011, 60:1237-1245.
26. Gottlieb, P. (2010) Webcast: Interim Results of a Phase I clinical Trial of a DNA Plasmid Vaccine (BHI-3021) for T1D. DiabetesPro [online], http://professional.diabetes.org/Presentations_Details.aspx%3Fsession=3575.
27. Achenbach P., et al. Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Curr. Diab. Rep. 2008, 8:87-93.
28. + T cells are involved in development and control of human autoimmune type 1 diabetes. J. Clin. Invest. 2010, 120:3641-3650.
29. Raz I., et al. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001, 358:1749-1753.
30. Elias D., et al. DiaPep277 preserves endogenous insulin production by immunomodulation in type 1 diabetes. Ann. N. Y. Acad. Sci. 2006, 1079:340-344.
31. ® is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial. Diabetes Metab. Res. Rev. 2007, 23:292-298.
32. Lazar L., et al. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab. Res. Rev. 2007, 23:286-291.
33. Schloot N.C., et al. Effect of heat shock protein peptide DiaPep277 on β-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diabetes Metab. Res. Rev. 2007, 23:276-285.
34. Stene L.C., et al. Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study. Am. J. Clin. Nutr. 2003, 78:1128-1134.
35. Norris J.M., et al. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. JAMA 2007, 298:1420-1428.
36. Pozzilli P., et al. Low levels of 25-hydroxyvitamin D3 and 1, 25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes. Horm. Metab. Res. 2005, 37:680-683.
37. Littorin B., et al. Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: results from the nationwide Diabetes Incidence Study in Sweden (DISS). Diabetologia 2006, 49:2847-2852.
38. Driver J., et al. Comparative therapeutic effects of orally administered 1, 25-dihydroxyvitamin D3 and 1alpha-hydroxyvitamin D3 on type-1 diabetes in non-obese diabetic mice fed a normal-calcaemic diet. Clin. Exp. Immunol. 2008, 151:76-85.
39. Cooper J.D., et al. Inherited variation in vitamin D genes is associated with predisposition to autoimmune disease type 1 diabetes. Diabetes 2011, 60:1624-1631.
40. Chase, H.P. (2010) Webcast: Nutritional Intervention to Prevent (NIP) type 1 diabetes, a pilot trial. DiabetesPro [online], http://professional.diabetes.org/Presentations_Details.aspx%3Fsession=3583.
41. Bizzarri C., et al. No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes. Diabetes 2010, 33:1962-1963.
42. Knip M., et al. Infant feeding and the risk of type 1 diabetes. Am. J. Clin. Nutr. 2010, 91:1506-1513.
43. Knip M., et al. Early feeding and risk of type 1 diabetes: experiences from the Trial to Reduce Insulin-dependent diabetes mellitus in the Genetically at Risk (TRIGR). Am. J. Clin. Nutr. 2011, 94(Suppl.):1814S-1820S.
44. Knip M., et al. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N. Engl. J. Med. 2010, 363:1900-1908.
45. Wen L., et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature 2008, 455:1109-1113.
46. Martin S., et al. Development of type 1 diabetes despite severe hereditary B-cell deficiency. N. Engl. J. Med. 2001, 345:1036-1040.
47. Hu C.Y., et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 2007, 117:3857-3867.
48. Wong F.S., et al. Investigation of the role of B-cells in type 1 diabetes in the NOD mouse. Diabetes 2004, 53:2581-2587.
49. Pescovitz M.D., et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 2009, 361:2143-2152.
50. Pescovitz, M.D. (2010) Webcast: Treatment of Type 1 diabetes with Rituxumab - 2 year follow up. DiabetesPro [online], http://professional.diabetes.org/presentations_details.aspx%3Fsession=3463.
51. Herold K.C., et al. Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. J. Immunol. 2011, 187:1998-2005.
52. + effector memory T cells based on CD2 expression. Am. J. Transplant. 2011, 11:22-33.
53. Lenschow D.J., et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 1995, 181:1145-1155.
54. + immunoregulatory T cells that control autoimmune diabetes. Immunity 2000, 12:431-440.
55. Londrigan S.L., et al. In situ protection against islet allograft rejection by CTLA4Ig transduction. Transplantation 2010, 90:951-957.
56. Orban T., et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011, 378:412-419.
57. Alegre M.L., et al. A non-activating " humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 1994, 57:1537-1543.
58. Chatenoud L. Immune therapy for type 1 diabetes mellitus - what is unique about anti-CD3 antibodies?. Nat. Rev. Endocrinol. 2010, 6:149-157.
59. Xu D., et al. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell. Immunol. 2000, 200:16-26.
60. Chatenoud L., et al. CD3 antibody-induced dominant self tolerance in overty diabetic NOD mice. J. Immunol. 1997, 158:2947-2954.
61. Belghith M., et al. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 2003, 9:1202-1208.
62. Chatenoud L., et al. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:123-127.
63. Herold K.C., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 2002, 346:1692-1698.
64. Herold K.C., et al. Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years. Clin. Immunol. 2009, 132:166-173.
65. Keymeulen B., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 2005, 352:2598-2608.
66. Keymeulen B., et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010, 53:614-623.
67. Sherry N., et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011, 378:487-497.
68. Gitelman, S.E. (2011) Webcast: AbATE (Anti-CD3 mAb). DiabetesPro [online], http://professional.diabetes.org/Presentations_Details.aspx%3Fsession=3791.
69. ® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin. Biochem. 1998, 31:335-340.
70. Grinberg-Bleyer Y., et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J. Exp. Med. 2010, 207:1871-1878.
71. Long S.A., et al. Rapamycin plus IL-2 combination therapy in subjects with T1D results in a sustained increase in IL-2 responsiveness and a transient decrease in C-peptide levels. Diabetes 2011, 60(Suppl. 1):A91.
72. Herold K.C., Bluestone J.A. Type 1 diabetes immunotherapy: is the glass half empty or half full?. Sci. Transl. Med. 2011, 3:95fs1.
73. Rabinovitch A., et al. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 2002, 51:638-645.
74. Elias D., Cohen I.R. Peptide therapy for diabetes in NOD mice. Lancet 1994, 343:704-706.
75. Elias D., Cohen I.R. Treatment of autoimmune diabetes and insulitis in NOD mice with heat shock protein 60 peptide p277. Diabetes 1995, 44:1132-1138.
76. Karges W., et al. Immunological aspects of nutritional diabetes prevention in NOD mice: a pilot study for the cow's milk-based IDDM prevention trial. Diabetes 1997, 46:557-564.
77. Shoda L.K.M., et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 2005, 23:115-126.
78. Babad J., et al. T-cell autoantigens in the non-obese diabetic mouse model of autoimmune diabetes. Immunology 2010, 131:459-465.
79. Bluestone J.A., et al. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010, 464:1293-1300.